Skip to main content
    G

    Greenwich Lifesciences Inc (GLSI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $18.70
    +4.94 (+35.90%)

    Market Cap: $201.97M

    Last updated: Nov 17, 2026 at 4:41 PM ET

    Greenwich Lifesciences Inc (GLSI) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Greenwich Lifesciences (GLSI) has a market cap of $201.97M and an enterprise value of $196.07M. Its share count is up 7.60% from a year earlier.

    Total Valuation

    Enterprise value is 2.92% below the market cap, as cash exceeds debt.

    Market Cap$201.97M
    Enterprise Value$196.07M
    Latest price (Nov 17, 2026)$18.70

    Key Dates

    The next earnings report is expected on Jun 2, 2027, covering the quarter ending Mar 31, 2027.

    Next Earnings DateJun 2, 2027 (expected)
    Last Earnings DateAug 11, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.39% in the quarter ended Sep 30, 2026 and grew 5.68% a year over 2 years.

    Shares Outstanding14.68M
    Shares Change (YoY)+7.60%
    Shares Change (QoQ)+0.39%
    Share Count Growth (2Y CAGR)+5.68%

    Price Statistics

    The stock is up 124.76% over 52 weeks and trades 12.79% above its 50-day average.

    Beta (1Y)3.12
    52-Week Change+124.76%
    1-Month Change+22.95%
    3-Month Change+7.84%
    6-Month Change-28.92%
    5-Year Change-50.76%
    Total Return (1Y)+124.76%
    Total Return (3Y CAGR)+20.41%
    Total Return (5Y CAGR)-11.84%
    Return vs SPY (1Y)+115.38%
    Max Drawdown (1Y)-61.87%
    Max Drawdown (3Y)-61.87%
    Sharpe Ratio (1Y)0.75
    Correlation with SPY (1Y)0.39
    50-Day Average$16.58
    200-Day Average$20.84
    52-Week Range$7.78 to $34.10
    RSI (14 Days)59.0
    Average Volume (20 Days)179.59K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.77x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio0.77x
    Quick Ratio0.77x
    Debt / Equity0.00x

    Scores

    GLSI has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Operating Income-$23.55M
    Pretax Income-$23.34M
    Net Income-$23.34M
    Reported EPS (TTM)-$1.54

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$5.90M
    Total Debt$0
    Net Cash$5.90M
    Net Cash Per Share$0.40
    Working Capital-$1.75M
    Shareholder Equity-$1.75M
    Total Assets$5.90M
    Total Liabilities$7.65M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$12.79M
    FCF Per Share-$0.87

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-78.24%
    Tangible Book Per Share Growth (2Y CAGR)-78.23%

    Revenue and profit by year

    Dividends and Yields

    GLSI does not pay a dividend.

    Buyback Yield-5.42%
    Shareholder Yield-5.42%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About GLSI

    What is GLSI's market cap?

    Greenwich Lifesciences has a market cap of $201.97M. Its enterprise value, which adds debt and subtracts cash, is $196.07M.

    How many shares of GLSI are outstanding?

    Greenwich Lifesciences has 14.68M shares outstanding. The count is up 7.60% from a year earlier.

    Does GLSI pay a dividend?

    No. Greenwich Lifesciences does not pay a dividend.

    How much debt does GLSI have?

    Greenwich Lifesciences has $0 of total debt and $5.90M of cash and equivalents, a net cash position of $5.90M.